Goldman Sachs says beaten down IGO share price can rise 30%+

Now could be the time to pounce on this battery materials share.

| More on:
A man holding a cup of coffee puts his thumb up and smiles while at laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The IGO Ltd (ASX: IGO) share price is falling again on Tuesday.

In afternoon trade, the battery materials producer's shares are down 2% to $9.50.

At one stage, IGO's shares were trading at a 52-week low of $9.34. This follows the release of a disappointing quarterly update on Monday.

Is the IGO share price in the buy zone now?

Analysts at Goldman Sachs have been running the rule over the quarterly update.

And while the broker acknowledges that some of the company's commentary regarding its lithium joint venture, Tianqi Lithium Energy Australia (TLEA), was a touch concerning, it believes the market has overreacted. It said:

The key focus though was TLEA having elected to not take its full spodumene entitlement from Greenbushes for the Dec-23 quarter (sales volumes expected to be ~25% below production) which we expect in part was driven by the emerging disconnect between the lagged pricing mechanism and spot spodumene prices, which sit ~30% below the Dec quarter reset price.

We expect this news was a significant contributor to IGO's underperformance (IGO stock -9% or ~A$700mn), though set out scenarios in Exhibit 3 outlining that the negative market reaction may have been overdone.

That exhibit essentially demonstrates that the net cash flow impact to IGO from this decision remains marginal at a range of spodumene prices.

In light of this, the broker believes investors should be snapping up the company's shares while they're so cheap. Especially given how the company's Greenbushes operation is the lowest-cost Australian spodumene producer, which leaves it well-positioned in the current environment. It adds:

[W]ith Greenbushes the lowest cost Australian spodumene producer, IGO noted that Greenbushes shareholders have a strong incentive to ensure volumes still flow to market. As such, while the stockpiling of volumes was the easiest solution in the near-term, we would expect a potential solution to be in place into the Mar-24 quarter via either a recut pricing mechanism (potentially removing lags/adding provisional pricing) or an agreed pecking order for offtake-deferred spot sales, mitigating the bulk of the impact beyond the Dec-23 quarter.

Major upside ahead

Goldman has a buy rating and a $12.70 price target on the company's shares. This implies a potential upside of approximately 34% for investors over the next 12 months.

In addition, the broker is forecasting an attractive 5.9% dividend yield in FY 2024. Though, it is worth highlighting that it expects this to fall to 1.7% in FY 2025 and FY 2026.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Market News

Big ASX 200 news! Market hits 8,700-point record high

It's an historic day for the ASX...

Read more »

Miner with thumbs up at mine
Broker Notes

Up 55% this year, does Macquarie rate Gold Road Resources shares a buy, hold or sell?

Does this strong performing gold miner have more room to run?

Read more »

Two happy woman on a couch looking at a tablet.
Opinions

Why I'm excited to see the results of these ASX 200 shares

These stocks could reveal very interesting insights.

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Morgans names 3 ASX stocks to buy

The broker is feeling very positive on the investment opportunities here.

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Share Market News

3 of the best ASX shares to buy with $5,000

These shares could be among the best to buy now according to Bell Potter.

Read more »

A woman holds her finger to the side of her lips in contemplation as she looks upwards to an array of graphic images of light bulbs above her head, one of which is on and glowing.
Share Market News

Macquarie tips more than 15% upside for this ASX 200 utilities stock

This ASX 200 stock could be set to rise.

Read more »

A woman stands at her desk looking a her phone with a panoramic view of the harbour bridge in the windows behind her with work colleagues in the background.
Share Market News

5 things to watch on the ASX 200 on Friday

Will the market end the week strongly? Let's find out.

Read more »